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Abstract: Epigenetics describes mechanisms which control gene expression and cellular processes
without changing the DNA sequence. The main mechanisms in epigenetics are DNA methylation
in CpG-rich promoters, histone modifications and non-coding RNAs (ncRNAs). DNA methylation
modifies the function of the DNA and correlates with gene silencing. Histone modifications
including acetylation/deacetylation and phosphorylation act in diverse biological processes such
as transcriptional activation/inactivation and DNA repair. Non-coding RNAs play a large part
in epigenetic regulation of gene expression in addition to their roles at the transcriptional and
post-transcriptional level. Osteoporosis is the most common skeletal disorder, characterized by
compromised bone strength and bone micro-architectural deterioration that predisposes the bones
to an increased risk of fracture. It is most often caused by an increase in bone resorption that is not
sufficiently compensated by a corresponding increase in bone formation. Nowadays it is well accepted
that osteoporosis is a multifactorial disorder and there are genetic risk factors for osteoporosis and
bone fractures. Here we review emerging evidence that epigenetics contributes to the machinery
that can alter DNA structure, gene expression, and cellular differentiation during physiological and
pathological bone remodeling.
Keywords: Genetics–Epigenetics; osteoporosis; bromodomain inhibitor; HDAC inhibitor;
bone regeneration
1. Introduction
The human skeleton is a metabolically active organ that undergoes continuous bone remodeling
throughout life [1]. The bone remodeling process involves the destruction of mineralized bone followed
by the formation of bone matrix that subsequently becomes mineralized. Bone remodeling is critical not
only for adapting bone architecture/strength to growth and mechanical needs, but also for repairing
microdamage and maintaining calcium homeostasis. The formation and resorption of bone are tightly
coupled and this orchestrated balance allows skeletal integrity. However, in certain physiological or
pathological conditions, the bone remodeling steps become uncoupled, leading to decreased bone
strength and increased fragility [2].
To maintain homeostasis of bone mass, the bone remodeling cycle involves a series of highly
regulated steps that depend on the interaction, differentiation and functions of two cell lineages:
the mesenchymal osteoblastic lineage and the hematopoietic osteoclastic lineage (Figure 1).
Int. J. Mol. Sci. 2016, 17, 1446; doi:10.3390/ijms17091446 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1446 2 of 14
Int. J. Mol. Sci. 2016, 17, 1446 2 of 14 
 
 
Figure 1. Bone remodeling cycle. A remodeling cycle is initiated by osteoclasts that solubilize bone 
mineral and degrade the matrix (resorption phase). Osteoclasts originate from hematopoietic stem 
cells which differentiate first into pre-osteoclast cells which fuse to form multinucleated cells 
(activated osteoclasts). Monocytes/macrophages remove debris (reversal phase), followed by a bone 
formation phase performed by osteoblasts, producing osteoid matrix which will mineralize. Growth 
factors are released from the bone matrix during resorption, which increase the pre-osteoblast 
population in order to replace damaged bone surfaces. 
On a molecular level, the differentiation and activation of bone cells are regulated by a complex 
signaling network involving both locally secreted factors and systemic hormones. Moreover, it is well 
established that several environmental and stochastic stressors including diet and chemical exposure 
can modulate through epigenetic mechanisms both gene expression and lineage decisions [3–5]. 
Thus, the pathological process of multi-factorial bone disorders such as osteoporosis could have an 
important epigenetic component. Epigenetic factors represent a promising area to link genetics and 
gene expression with disease risk. A deeper understanding of the molecular and epigenetic 
regulation of bone cell differentiation and functions will allow us to design and develop new 
treatments for osteoporosis. 
2. Epigenetic Regulation of Bone Remodeling 
Osteoblasts, bone-forming cells, are derived from mesenchymal stem cells (MSCs). Differentiation 
of MSCs into specialized cells involves an upregulation of genes involved in differentiation of a specific 
cell phenotype and downregulation of genes responsible for cell stemness [6]. Key genes for the 
maintenance of stem cells and their differentiation into particular cell lineages show evidence of 
epigenetic regulations [7]. These non-genetic alterations are regulated by three main epigenetic 
modifications: DNA methylation, histone modifications and non-coding RNAs (ncRNAs). 
  
Figure 1. Bone remodeling cycle. A remodeling cycle is initiated by osteoclasts that solubilize bone
mineral and degrade the matrix (resorption phase). Osteoclasts originate from hematopoietic stem
cells which differentiate first into pre-osteoclast cells which fuse to form multinucleated cells (activated
osteoclasts). Monocytes/macrophages remove debris (reversal phase), followed by a bone formation
phase performed by osteoblasts, producing osteoid matrix which will mineralize. Growth factors are
released from the bone matrix during resorption, which increase the pre-osteoblast population in order
to replace damaged bone surfaces.
On a molecular le el, the differentiation an tivation of bone cells are regulated by a complex
signaling network involving both locally secreted factors and systemic hormones. Moreover, it is well
established that several environmental and stochastic stressors including diet and chemical exposure
can modulate through epigenetic mechanisms both gene expression and lineage decisions [3–5].
Thus, the pathological process of multi-factorial bone disorders such as osteoporosis could have
an important epigenetic component. Epigenetic factors represent a promising area to link genetics
and gene expression with disease risk. A deeper understanding of the molecular and epigenetic
regulation of bone cell differentiation and functions will allow us to design and develop new treatments
for osteoporosis.
2. Epigenetic Regulation of Bone Remodeling
Osteoblasts, bone-forming cells, are derived from mesenchymal stem cells (MSCs). Differentiation
of MSCs i to specialized cells i volves an upregulation of genes involved in differentiation of a specific
cell h o ype and downregulatio of genes responsible for cell stemness [6]. Key gen s for the
maintenance of stem cells and their different ation into particular cell lineages show evidence of
epigenetic regulations [7]. These non-genetic alterations are regulated by three main epigenetic
modifications: DNA methylation, histone modifications and non-coding RNAs (ncRNAs).
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3. DNA Methylation
DNA methylation, a well-characterized epigenetic modification, is associated with transcriptional
silencing. DNA methylation occurs at the 5′ position of the cytosine ring within CpG dinucleotides and
is catalyzed by DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b [8,9].
DNA methylation is essential for normal development and is associated with gene silencing (Figure 2).
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DNA and represses gene expression. 
In humans, CpG totals for ~1% and 60%–80% of CpGs are methylated, mainly in heterochromatic 
regions [10]. Abnormal patterns of DNA methylation influence diseases processes, especially in 
human tumors [11–14]. Several studies have suggested that DNA methylation plays an important 
role in osteoblast differentiation. Promoter methylation changes were observed during the osteogenic 
differentiation of MSCs. Indeed, in the differentiation of mesenchymal cells towards osteoblastic 
lineage runt related transcription factor 2 (Runx2) and osteocalcin genes exhibited hypomethylation of 
the CpGs along with their strong expression [15]. It has been shown that active demethylation of the 
promoters of Runx2, osteocalcin and osterix genes by growth arrest and DNA-damage-inducible 
protein (GADD45)-dependent mechanisms is involved in the osteogenic differentiation of adipose-
derived MSCs [16]. Interestingly, a recent study showed that wingless/int-1 homolog (Wnt)3a 
stimulates osteoblast differentiation only in cells with intrinsic osteogenic potential and not in fat cell 
precursors or fibroblasts [17]. Wnt3a promotes osteoblast differentiation by stimulating bone 
morphogenetic protein 2 (BMP2) production. In non-osteogenic cells, CpGs islands in BMP2 and 
alkaline phosphatase (ALP) promoters show increased methylation leading to prevention of  
their expression. Moreover, treatment of these non-osteogenic cells with 5′-aza-2′-deoxycytidine,  
a CpG-demethylating agent, makes BMP2 and ALP genes receptive to Wnt3a [17]. 
DNA methylation marks are also important for the crosstalk between osteoblasts and 
osteoclasts. Osteoblasts express receptor activator of nuclear factor-kappa B ligand (RANKL) on the 
extracellular surface of their plasma membrane, which binds to RANK, activating signaling pathways 
that promote osteoclast differentiation and survival. Higher levels of CpG methylation of the RANKL 
promoters were detected in various tissues expressing low or no levels of RANKL [18]. Consistently, 
Figure 2. DNA methylation and gene expression. (a) DNA methylation occurs at cytosine bases
(CpG islands) when a methyl group is added at the 5′ position on the pyrimidine ring by DNA methyl
transferases (DNMTs); (b) Two types of DNMTs initiate de novo DNA methylation; DNMT3a and
DNMT3b to methylate previously unmethylated cytosines (C), whereas maintenance DNMTs (DNMT1)
methylate hemi-methylated DNA at the complementary strand; (c) Methyl group tags DNA and
represses gene expression.
In humans, CpG totals for ~1% and 60%–80% of CpGs are m thylated, mainly in heterochromatic
regions [10]. Abnormal patt ns of DNA methylation influence diseases proces es, especially in
human tumors [11–14]. Several studies have suggested that DNA methylation plays an important
role in osteoblast differentiation. Promot r methylation changes were observed during the steogenic
differentiation of MSCs. Indeed, in the differentiation of mesenchymal cells towards osteoblastic
lineage runt related transcription factor 2 (Runx2) and osteocalcin genes exhibited hypomethylation of
the CpGs along with their strong expression [15]. It has been shown that active demethylation of the
promoters of Runx2, osteocalcin and osterix genes by growth arrest and DNA-damage-inducible protein
(GADD45)-dependent mechanisms is involved in the osteogenic differentiation of adipose-derived
MSCs [16]. Interestingly, a recent study showed that wingless/int-1 homolog (Wnt)3a stimulates
osteoblast differentiation only in cells with intrinsic osteogenic potential and not in fat cell precursors
or fibroblasts [17]. Wnt3a promotes osteoblast differentiation by stimulating bone morphogenetic
protein 2 (BMP2) production. In non-osteogenic cells, CpGs islands in BMP2 and alkaline phosphatase
(ALP) promoters show increased methylation leading to prevention of their expression. Moreover,
treatment of these non-osteogenic cells with 5′-aza-2′-deoxycytidine, a CpG-demethylating agent,
makes BMP2 and ALP genes r ceptive t Wnt3a [17].
DNA methylation marks are also important for t e crosstalk between osteoblasts and osteoclasts.
Osteoblasts express receptor activator of uclear f ctor-kappa B ligand (RANKL) the extracellular
surface of their plasma membrane, which binds to RANK, activating signaling pathways that promote
osteoclast differentiation and survival. Higher levels of CpG methylation of the RANKL promoters
were detected in various tissues expressing low or no levels of RANKL [18]. Consistently, treatment
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with the DNA demethylating agent 5′-aza-2′-deoxycytidine promoted a 170-fold induction of RANKL
mRNA expression in HEK-293 cells, which showed hypermethylation of the CpG islands and hardly
expressed RANKL transcript at baseline [18]. Conversely, treatment with DNA methyltransferase
inhibitor restored RANKL expression, suggesting that CpG methylation of the RANKL promoter
reversibly suppresses RANKL gene expression. DNA methylation affects not only the genes that
activate osteoclast differentiation but also those that repress it. Recently, it has been shown that DNA
methylation by DNMT3a, mediated by S-adenosylmethionine (SAM), regulate osteoclastogenesis
by epigenetic repression of interferon regulatory factor 8 (IRF8) [19]. IRF8 is a key negative regulator
of osteoclast phenotype that needs to be epigenetically silenced for osteoclastogenesis to proceed.
In an in vivo model, mice that lacked Dnmt3a in their osteoclasts showed higher bone mass due to
a reduced number of osteoclasts, suggesting the role of DNMT3a in bone homeostasis [19].
Beside osteoclasts and osteoblasts, osteocytes represent the third and the far most abundant
bone cell type. Osteocytes are considered to be osteoblasts that have reached their ultimate state of
differentiation and become progressively embedded in mineralized bone. The osteoblast-to-osteocyte
transition is also modulated by DNA methylation. The expression of ALP and sclerostin (SOST) genes is
regulated by CpG methylation [20]. Indeed, hypermethylation of ALP and SOST promoters negatively
correlates with gene expression in osteoblastic cells. Moreover, the methylation of those promoters
changes during osteoblast-to-osteocyte transition and controls gene expression in acell-specific
manner [21,22]. The number of genes important for osteoblast and osteoclast differentiation and
for the osteoblast-to-osteocytes transition are regulated by DNA methylation [23–25]. However,
other epigenetic modifications, such as chromatin modifications and ncRNA gene regulations, are also
involved in the differentiation and activity of bone cells [26].
4. Histone Modifications
Histone modification is another epigenetic mechanism that regulates gene expression.
In eukaryotic cells, DNA is complexed with histones which leads to its compaction and assembly into
the basic unit of chromatin—the nucleosome. Histone modifications are key components of epigenetic
regulation by which the cells regulate transcription, replication and repair [23]. Modifications occur on
accessible tails and can regulate chromatin structure (Figure 3).
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Figure 3. Nucleosome with histone post-translational modifications. Inside the nucleus DNA is wrapped
into a protein complex known as chromatin. This protein complex (nucleosome) is composed of an octamer
of four different histones (H3, H4, H2A, and H2B). Histones display a large number of modified
residues (acetylation, methylation, phosphorylation and ubiquitylation). Through these modifications,
chromatin becomes very dynamic, controlling the expression or repression of specific genes.
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In addition to the well-characterized acetylation, methylation, phosphorylation and ubiquitylation
modifications, recent studies have revealed other new types of histone marks such as propionylation,
butyrylation, malonylation, glycosylation, etc. [27–29]. The main reversible histone modifications are
listed in Table 1.
Table 1. The main reversible histone modifications.
Enzyme Target Modification References
Histone acetyltransferases (HATs),
Histone deacetylases (HDACs) Lysine
Acetylation
Deacetylation [30–33]
Lysine methyltransferases,
arginine methyltransferases
Lysine
Arginine
Methylation
Demethylation [34–36]
Kinases, phosphatase
Serine
Threonine
Tyrosine
Phosphorylation
Dephosphorylation [37]
Ubiquitin ligase (E3) and ubiquitin-activating enzyme
(E1/E2), Small Ubiquitin-like Modifier (SUMO) Lysine
Ubiquitylation
Sumoylation
Deubiquitylation
[38]
Poly (ADP-ribose) polymerase (PARP) GlutamateArginine ADP-ribosylation [38,39]
The histone lysine acetylation (Kac) has been widely studied and shown to be closely linked to
transcriptional regulation. Early studies revealed the association of hyperacetylated histones, which results
in uncompressed chromatin, with actively transcribed genes, suggesting a role for histone acetylation in
gene activation by increasing the accessibility of DNA to the transcription machinery [40,41]. In contrast,
histone deacetylation results in condensed chromatin, leading to gene inactivation. The addition of
acetyl groups on lysine residues in histone tails implicates lysine acetyltransferases (KATs)/histone
acetyltransferases (HATs), whereas their elimination involves histone deacetylases (HDACs).
In several bone candidate genes, histone modifications have been studied in terms of their
effects on gene expression and cell differentiation. In murine bone stromal cells, the histone deacetylase
inhibitors trichostatin A (TSA) and sodium butyrate strongly increased RANKL promoter activity through
enhanced acetylation of histone H3 and H4 [42]. However, unlike what is expected, TSA suppressed
RANKL-induced osteoclast formation from primary bone marrow-derived macrophages, suggesting
that the effects of these histone modifications must be taken into account as cell-specific consequences
as well as in a broader context [43].
Recently, Rojas et al. showed that the epigenetically-forced expression of Runx2 and osteocalcin,
classical bone-related target genes, under myoblastic differentiation is accompanied by enrichment
of the H3K4me3 and H3K27ac marks at the Runx2 promoter region [44]. These authors identified
JARID1B, also known as lysine (K)-specific demethylase (KDM)5B, as a key and potent epigenetic
switch which controls mesenchymal cell differentiation into myogenic and osteogenic lineages.
During osteoblast differentiation, acetylation of histone H3 and H4 were significantly enhanced at the
promoters of the osterix and osteocalcin genes, osteoblast markers genes, whereas histone deacetylase 1
(HDAC1) recruitment at those promoters was downregulated [45]. Moreover, knockdown of HDAC1
by the short interference RNA (siRNA) stimulated osteoblast differentiation. It was also shown
in a recent study that the treatment of non-osteogenic cells with TSA allows Wnt3a to promote
osteogenesis in these cells, suggesting that direct conversion of non-osteogenic cells into osteoblastic
cell types without inducing pluripotency might be controlled by histone modifiers [17].
5. Non-Coding RNAs
Although 90% of genomic DNA is transcribed into RNA, only 1%–2% of the human genome
encodes for proteins [46]. A vast majority of RNA is an end product not used to make proteins
and is represented by ncRNAs. These ncRNAs play significant roles in the regulation of gene
expression through transcriptional and post-transcriptional regulation [47,48]. Non-coding RNAs can
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be divided into two main groups: infrastructural and regulatory ncRNAs. Since they are involved
in the modification and regulation of other RNAs, regulatory ncRNAs are considered as epigenetic
modifiers. They can be categorized into six groups: microRNAs (miRNAs), P-element induced wimpy
testis (piwi)-interacting RNAs (piRNAs), siRNAs, long non-coding RNAs (lncRNAs), enhancer RNAs
(eRNAs), and promoter-associated RNAs (PARs). These ncRNAs are characterized by different lengths
and different functions (Table 2).
Table 2. Non-coding RNA (ncRNA) and their characteristics and functions.
Name Length (nt) Characteristic and Function
MicroRNA (miRNA) 20–24
• Single-stranded RNA (ssRNA)
• derived from pre-miRNA (hairpin)
• gene silencing
Piwi-interacting RNA (piRNA) 24–31
• Form complexes with P-element induced wimpy testis (Piwi) proteins of the
Argonaute family
• silencing of transposable elements
Small interfering RNA (siRNA) 20–24
• Double-stranded RNA (dsRNA) processed by endoribonuclease Dicer into
mature siRNA
• post-transcriptional silencing/RNA interference (RNAi)
• protection against viral infection
Promoter-associated RNA (PAR) 16–200
• ssRNA with short half-life
• Post-transcriptional regulation
Enhancer RNA (eRNA) 100–9000
• ssRNA with short half-life
• trasncriptional gene activation
Long non-coding RNA (lncRNA) >200
• Non-protein coding transcripts
• Subject to post-transcriptional modifications
• Transcriptional/post-transcriptional regulation and precursor for siRNA
Based on the length, ncRNAs can be divided into two groups: the short ncRNAs (<30 nts) and the
long ncRNAs (lncRNAs) (>200 nts) however, both groups are shown to play a role in heterochromatin
formation, histone modification, DNA methylation targeting, and gene silencing [49]. Despite the fact
that lncRNAs are key regulators of diverse biological processes such as cell growth and differentiation,
little is known about whether they regulate bone cell differentiation and bone homeostasis. However,
a recent study has demonstrated that anti-differentiation ncRNA (ANCR) which is affiliated with
the lncRNA class and more recently named differentiation antagonizing non-protein coding RNA
(DANCR) is an essential mediator of osteoblast differentiation [50]. DANCR overexpression is
sufficient to inhibit osteoblast differentiation and DANCR-siRNA promotes osteoblast differentiation.
More recently, Tong et al. showed that the expression of DANCR is upregulated in blood mononuclear
cells from low bone mineral density (BMD) patients. DANCR promotes the expression of interleukine
(IL)-6 and tumor necrosis factor (TNF)-α, and the level of DANCR was correlated with IL-6 and TNF-α
in postmenopausal women [51].
The most studied ncRNAs in relation to bone homeostasis and bone diseases are miRNAs.
In the last decade a large number of miRNAs were clearly and closely associated to the development
and metabolism of bone. Additionally, the altered expression levels of some miRNAs can cause
bone metabolism disorders leading to osteoporosis [52–54]. Many studies have reported that the
expression of certain miRNAs in osteoblast and osteoclast differentiation appears upregulated or
downregulated [55–60]. Among all described miRNAs, there are two groups: miRNAs promoting
differentiation and miRNAs inhibiting differentiation of bone cells (Table 3A).
In bone homeostasis preservation, osteoblast differentiation is an important process. Osteoblast
lineage commitment is tightly regulated at both transcriptional and post-transcriptional levels.
Runx2, a master regulator of osteoblast differentiation, controls the expression of bone-related genes.
Transcriptional regulation of Runx2 gene in mesenchymal progenitor cells is controlled by several
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miRNAs. For instance, during adipocyte differentiation miR-204 expression is induced, whereas
Runx2 protein expression is suppressed, suggesting that miR-204 acts as an inhibitor of Runx2 [61].
The involvement of miRNAs in osteoblast differentiation can also be indirect. In this context, it was
recently shown that miR-15b promotes osteoblast differentiation by protecting Runx2 protein from
mothers against decapentaplegic homolog (SMAD) specific E3 ubiquitin protein ligase 1 (Smurf1)
mediated degradation [62]. Compared to osteoblast differentiation, the impact of miRNAs on osteoclast
differentiation has been less studied [60–63] (Table 3B).
Table 3. Example of functional miRNAs in osteoblast (A) and osteoclast (B) differentiation.
miRNAs Target Effect References
A. Osteoblast Differentiation
miR-216-a PI3K/AKT pathway E [64]
miR-21 SMAD7 E [65]
miR-194 STAT1 E [66]
miR-96 EGFR signaling E [67]
miR-23-a GjA1 I [68]
miR-375 Runx2 I [69]
miR-153 BMPRII I [70]
miR-124 Dlx5, Dlx3, Dlx2 I [71]
B. Osteoclast Differentiation
miR-214 PTEN/AKT pathway E [60]
miR-183 Heme oxygenase-1 E [72]
miR-9718 PIAS3 E [73]
miR-17/20a RANKL I [59]
miR-26-a CTGF I [74]
miR-7-b DCSTAMP I [75]
miR-34-a TGIF2 I [76]
miR-126-5p MMP13 I [77]
E, enhances; I, inhibits. AKT, protein kinase B/serine-threonine protein kinase; BMPRII, bone morphogenetic
protein receptor type II; CTGF, connective tissue growth factor; DCSTAMP, dendritic cells-specific transmembrane
protein; Dlx, distal-less homeobox; EGFR, epidermal growth factor receptor; GjA1, gap junction protein alpha 1;
MMP, matrix metallopeptidase; SMAD7, mothers against decapentaplegic homolog 7; PTEN, phosphatase and
tensin homolog; PIAS3, protein inhibitor of activated STAT 3; PI3K, phosphatidylinositol-4,5-bisphosphate
3-kinase; RANKL, receptor activator of nuclear factor-kappa B ligand; Runx2, runt related transcription factor 2;
STAT1, signal transducer and activator of transcription 1; TGIF2, TGFB induced factor homeobox 2.
Nonetheless, the expression pattern of miRNAs during the osteoclast differentiation has been
explored and has shown changes in several miRNAS [78,79]. Recently the functions of relevant
miRNAs in osteoclasts and related bone diseases, such as osteoporosis, have been summarized [80].
Osteoclasts are derived from mononuclear macrophages and the most important step in osteoclast
differentiation is the fusion of mononucleated cells to form multinucleated cells. Dendritic cells-specific
transmembrane protein (DCSTAMP) is a key regulator of osteoclast cell fusion and differentiation [81,82].
By targeting DCSTAMP, miR-7b inhibited osteoclastogenesis and cell fusion. The inhibition of DCSTAMP
influences the expression of other genes involved in osteoclast fusion and differentiation such as
nuclear factor of activated T-cells 1 (NFATC1), C-Fos, protein kinase B/serine-threonine protein kinase
(AKT) and TNF receptor associated factor 6 (TRAF6) [75]. Recently it was shown that connective
tissue growth factor/CCN family 2 (CTGF/CCN2), which can promote osteoclast formation via
upregulation of DCSTAMP is targeted by miR-26a [74]. The overexpression of miR-26a inhibitor
enhanced RANKL-induced osteoclast formation and function as well as CTGF expression, suggesting
that miR-26a modulates osteoclast formation and function through the regulation of CTGF.
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6. Epigenetic and Osteoporosis
Osteoporosis is a skeletal disorder characterized by a reduction of bone strength and increased risk
of bone fracture. Many factors influence bone homeostasis and bone mineral accumulation including
heredity, gender, diet, physical activity, endocrine status, and sporadic risk factors such as smoking.
In addition to these modifiable factors during childhood, evidence has also accrued that fracture risk
might be programmed during intrauterine life. Lately, the involvement of epigenetic gene regulation
in many diseases has been documented making it an important target for basic and clinical research
for multifactorial diseases including osteoporosis.
The number of studies suggesting that epigenetic modifications play an important role in
bone homeostasis and BMD has become increasingly significant [83–85]. The osteoprotegerin
(OPG)/RANKL system is important in the equilibrium between bone formation and bone resorption.
The alteration of this system is also involved in bone loss that characterizes osteoporotic patients [86].
The association between OPG:RANKL ratio and DNA methylation has recently been proposed to
explain, at least partially, osteoclast activation and osteoporotic fractures [18]. It is well established that
estrogen deficiency induces osteoporosis. Methylation of the promoter A region in the estrogen receptor
alpha (ERα) gene, which leads to a decrease ERα mRNA, is increased in post-menopausal women than
pre-menopausal women [87]. Thus, DNA methylation seems to be an important mechanism for the
pathogenesis of osteoporosis. However, other mechanisms appear to be involved in the emergence
of osteoporosis. Indeed, histone modifications impact bone cell differentiation and ultimately the
onset of osteoporosis. During osteoporosis, the imbalance between bone mass and fat increases the
risk of fracture. The histone demethylases KDM4B and KDM6B play critical roles in osteogenic
commitment of MSCs by removing methyl group from H3K9 and H3K27. Depletion of KDM4B or
KDM6B significantly reduces osteogenic differentiation and increases adipogenic differentiation [88].
In ovariectomized mice H3K27me and H3K9me-positive MSCs were significantly elevated suggesting
a link between histone modifications and osteoporosis. Other studies showed the impact of histone
modifications on MSC differentiation and their implication in bone fracture risk. On the promoters of
Wnts (Wnt1, Wnt6 and Wnt10) histone methylation (H3K27me) by the enhancer of zeste homolog 2
(EZH2) inhibits Wnt genes transcription. This Wnt/β-catenin pathway inhibition is responsible of
the shift of MSC lineage commitment towards adipocytes [89]. The shift of MSCs towards adipogenic
differentiation is also controlled by HDACs. Indeed, the suppression of HDAC3 activity contributes to
increase marrow adiposity associated with aging bone and osteoporosis [90]. Given that histones are
chemically modifiable, handling their activities represents a potential and promising way to treat bone
diseases such as osteoporosis.
There is accumulating evidence that miRNAs play a critical role in the regulation of various
biological processes including bone homeostasis. MicroRNAs have been deeply involved in the
regulation of bone cells differentiation and bone resorption. Recent studies demonstrated that the
expression of several miRNAs is markedly upregulated in the serum of patients with osteoporotic
fractures and can influence osteogenic differentiation [54,91]. Since miRNAs are the most abundant
RNA species to be found in circulation, quantification of their expression may be used as biomarker for
diagnostic purposes and may be a target for drug development [92–94]. Compounds targeting specific
miRNAs are currently in clinical trials for the treatment of cancer [95] or type II diabetes [96]. In a recent
study, resveratrol, which is a polyphenolic phytoestrogen with osteogenic and osteoinductive
properties, exhibited the ability to prevent osteoporosis by suppressing miR-338-3p. Mechanistically,
resveratrol treatment leads to suppressed miR-338-3p, followed by an increase in Runx2 expression [97].
7. Epigenetically Active Drugs and Bone Homeostasis
In the last few decades, HDAC inhibitors and bromodomain (BRD) inhibitors were developed to
serve as anticancer drugs via inhibiting the deacetylation of histones or the recognition of acetyl-lysine
groups on histones or non-histone proteins respectively [98,99]. For bone homeostasis the regulation of
SOST expression was found to be an important target of HDACs, since SOST inhibits bone formation
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by antagonizing canonical Wnt signaling, which is required for normal osteoblastogenesis and control
of osteoclastogenesis [100]. SOST gene expression was found to be negatively regulated by HDAC5
by inhibiting myocyte enhancer factor 2 (Mef2) and positively regulated by class I HDACs [100].
The bone anabolic effect of the HDAC I inhibitor MS-275, however, was also found to derive from
interference with the DExH-box helicase Dhx36 [101]. In essence, class I HDAC inhibitors represent
a novel approach for bone forming osteoporosis therapies [100].
Inhibitors of the BRD target osteoblastogenesis via Runx2 inhibition and osteoclastogenesis
via inhibition of Myc and nuclear factor kappa B (NFκB) [102]. In the context of the treatment
of osteoporosis and bone loss, BRD inhibitors have shown in vitro and in vivo promising results
presumably due to their activity to inhibit osteoclastogenesis and inflammation [98,102–107].
Indeed, DNA methylation and histone modifications such as acetylation could be recognized by
BRD-containing proteins and selective BRD inhibitors seem to be a new epigenetic approach to treat
bone-related diseases. For example, the BRD inhibitor I-BET151 targets an epigenetic mechanism
important for osteoclast differentiation and demonstrates therapeutic efficacy by preserving bone mass
and strength in an ovariectomy-based model of osteoporosis [108]. In light of the strong inhibition of
Runx2 expression, however, BRD inhibitors might not be ideally suited for osteoporosis treatment, since
the transcription factor Runx2 is needed for the onset of osteoblast differentiation from MSCs [109].
In contrast to high affinity BRD inhibitors like JQ1 or I-BET151, low affinity BRD inhibitors like
N-methyl pyrrolidone (NMP) were shown to facilitate differentiation of osteoblasts from human MSCs,
enhance bone regeneration and bone formation [110]. During the last few years, we demonstrated that
NMP stimulates bone formation and inhibits osteoclast differentiation and bone resorption [103,110].
Furthermore, we established that this small bioactive molecule acts as a BRD inhibitor and is able to
inhibit inflammatory mediators and to prevent bone loss in an animal model of osteoporosis [104,105].
In essence, the low affinity BRD inhibitor NMP is suited for osteoporosis treatment since inflammation
and bone degradation are reduced and at the same time bone formation enhanced.
8. Conclusions
This review illustrates that epigenetic regulation is deeply involved in bone homeostasis and
that epigenetic-based therapeutics have already shown potential for the treatment of osteoporosis.
Epigenetically active drugs like HDACS and BRD inhibitors target several genes and pathways,
therefore further studies are required to translate these findings to clinical trials and later to patients.
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